Ossiform, We Print Bone™, is pleased to announce that it has completed a £6 million capital raise through West Hill Capital. Ossiform has developed a disruptive and patented technology to produce and supply P3D Bone; 3D printed patient-specific, resorbable bone implants that remodel into real living bone. Positive testing results toward FDA clearance have been obtained, and sales of Ossiform’s 3D printed R&D products for enhancing bone and cancer research, the P3D Scaffolds, have been established internationally.
The raised capital will be used to get the P3D Bone to market and reach its first clinical use in the USA in 2023, and to establish the production line for the fully patient specific P3D Bone.
RELATED: Volumina Medical closes its Series A funding
“We are very pleased to collaborate with West Hill raising the capital needed to expand our activities and prepare our P3D Bone for the US$3.8 billion bone implant market, and despite the current crises we succeeded.”, says Thea Wulff Olesen, CEO of Ossiform.
Robert Caie, Managing Partner at West Hill Capital, added, “West Hill is once again delighted to be supporting Ossiform in the next stage of the Company’s development. This fascinating technology has the potential to transform how millions of patients receive implants every year by eliminating complications, reducing the cost of treatment, and dramatically improving functional and aesthetic outcomes.”
Ossiform
Ossiform is dedicated to improving the lives of people with bone defects. We provide patient specific, natural, and resorbable bone implants to reduce complications, improve functional and aesthetic outcomes and obtain faster recovery. We are continuously working to redefine bone replacements through progressive research and close collaboration with physicians. Our patient-centric approach and commitment to quality, trust, and innovation steer our efforts to provide best-in-class implant solutions that facilitate the natural forming of new bone.
Follow the latest news on Guided Solutions
